CIA
CRSP icon

Choate Investment Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Choate Investment Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202K Buy
+3,704
New +$195K ﹤0.01% 461
2025
Q4 		– Sell
-3,304
Closed -$214K – 447
2025
Q3 		$214K Buy
+3,304
New +$190K ﹤0.01% 399
2024
Q2 		– Sell
-3,654
Closed -$249K – 383
2024
Q1 		$249K Hold
3,654
– – 0.01% 357
2023
Q4 		$229K Buy
+3,654
New +$202K 0.01% 345
2021
Q3 		– Sell
-1,704
Closed -$276K – 311
2021
Q2 		$276K Buy
+1,704
New +$207K 0.02% 236

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Choate Investment Advisors's CRSP Position: Q2 2026 in Review

Choate Investment Advisors opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 3,704 shares worth $202K. The stake represents ﹤0.01% of the portfolio and ranks #461 among its holdings. This is a return to the name: Choate Investment Advisors previously reported a position in CRSP as recently as Q3 2025.

Choate Investment Advisors first reported a position in CRSP in Q2 2021 and has held it in 5 quarters since. The position peaked at $276K in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Choate Investment Advisors held 3,704 shares of CRISPR Therapeutics worth $202K as of Q2 2026.
  • CRISPR Therapeutics was a new Choate Investment Advisors position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Choate Investment Advisors's portfolio in Q2 2026, its #461 holding.
  • Choate Investment Advisors first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 5 quarters since.
  • Choate Investment Advisors's CRISPR Therapeutics position peaked at $276K in Q2 2021.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Choate Investment Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.